M.P. Vélez1,*, M.P. Connolly2,3, I.-J. Kadoch1,4, S. Phillips4 and F. Bissonnette1,4 Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Montreal, Montreal, Canada Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics, University of Groningen, Groningen, Netherlands Global Market Access Solutions, St-Prex, Switzerland...

Pharmacoeconomics and health outcomes research are playing an increasingly important role in informing clinical development and market access decisions of new innovative medicines. Both disciplines are dealing with the evaluation of the costs and outcomes of healthcare interventions and can be considered as two branches of the same “value for money” tree. Pharmacoeconomics is the part of health...

The Canadian Common Drug Review (CDR) was established in 2003 to Abstract provide a single process for making formulary recommendations to most Canadian publicly funded drug plans. This paper considers the most common challenges faced by the CDR: (a) determining the effectiveness of a drug (particularly interpreting the importance of surrogate markers and changes in QOL measures); (b) the massi...

Pharmaceutical patents are anachronistic holdovers from an era in which Abstract modern economic understanding and tax tools were unavailable. Superior mechanisms lie somewhere between a first best pricing solution for the entire economy at one extreme and the current arrangements at the other. We discuss the economics of suggested alternatives and suggest that the intertemporal bounty is the b...

Indirect and mixed treatment comparison (MTC) approaches to synthesis are Abstract logical extensions of more established meta-analysis methods. They have great potential for estimating the comparative effectiveness of multiple treatments using an evidence base of trials that individually do not compare all treatment options. Connected networks of evidence can be synthesized simultaneously to p...